CELLULAR INTERACTIONS RESPONSIBLE FOR DEVELOPMENT, MAINTENANCE, AND STRENGTH OF THE SKELETON
With
Prof Natalie A Sims, PhD.
Deputy Director, St. Vincent’s Institute,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | May 2025
Professor Sims directs the Bone Cell Biology and Disease Unit at St. Vincent’s Institute of Medical Research and is a Professorial Fellow at The University of Melbourne and Australian Catholic University.
She leads a team who studies the cellular interactions responsible for development, maintenance, and strength of the skeleton. She completed her PhD at the University of Adelaide, followed by postdoctoral work at the Garvan Institute in Sydney then at Yale School of Medicine, in New Haven, Connecticut, where she studied the role of the estrogen receptor in regulating bone structure.
She returned to Australia in 2001 to set up a laboratory at St. Vincent’s Hospital and SVI. Her laboratory studies the cellular interactions responsible for development, maintenance, and strength of the skeleton, including the IL-6 family of cytokines, using genetically altered mouse models, in vitro system and human specimens. She has published more than 140 peer reviewed original research articles, 48 peer reviewed review articles and commentaries, and 20 published chapters; H index of 64 (Scopus); more than 13,500 career citations.
Her work has been recognised by awards from her colleagues internationally, including the International Bone and Mineral Society Herbert A Fleisch Award (2013) and the American Society of Bone and Mineral Research (ASBMR) Fuller Albright Award (2010) and Paula Stern Award (2020).
She is a Deputy Editor of the Journal of Bone and Mineral Research and serves on the Editorial Board of the Journal of Biological Chemistry. She has served as President of the Australia and New Zealand Bone and Mineral Society and is currently Executive Secretary of the International Federation of Musculoskeletal Research Societies.
Source: Supplied
-
Touched by bowel cancer and chasing science outcomes
Dr Josephine Wright is a Senior Research Fellow in the Gut Cancer group. She has been developing a translational network of labs, hospitals and clinics to enable validation of new approaches to prevent and treat colorectal and gastric cancer. Her key focus is studying human tumour organoids to better personalise therapy in cancer.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
-
Infections and other lung diseases using models of human lung tissue grown from stem cells
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
